Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of Tempol (MBM-02) in Subjects With COVID-19 Infection

Next Previous
Trial Profile

A Phase 2/3, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of Tempol (MBM-02) in Subjects With COVID-19 Infection

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 08 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tempol (Primary)
  • Indications COVID 2019 infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Adamis Pharmaceuticals Corporation

Most Recent Events

  • 21 Sep 2022 Status changed from recruiting to discontinued, according to an Adamis Pharmaceuticals Corporation media release,
  • 21 Sep 2022 Primary endpoint has not been met. (Difference in the rate of sustained clinical resolution1 of symptoms of COVID-19), according to an Adamis Pharmaceuticals Corporation media release.
  • 21 Sep 2022 According to an Adamis Pharmaceuticals Corporation media release, the independent Data Safety Monitoring Board (DSMB) after third planned interim analysis has recommended to halt study early due to lack of efficacy. The DSMB did note that no safety concerns were identified in the subjects that received Tempol. Based on the recommendation from the DSMB, the Company has halted the trial and will now evaluate the unblinded data from the trial to determine the next developmental steps for Tempol.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top